Similar Items: Systemic and ocular complications related to intravitreal administration of anti-VEGF agents
- Clinical Outcomes of Neovascular Glaucoma in Patients with Prior and Non-Prior Intravitreal Anti-VEGF Treatment: A Retrospective Cohort Study
- Real-World Persistence with Anti-VEGF Therapy in Neovascular Age-related Macular Degeneration
- Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval
- The Evolving Role of Anti-VEGF Therapy in Proliferative Diabetic Retinopathy: Evidence, Challenges, and Future Directions
- Macular Neovascular Membrane as a Late Complication of Acute Posterior Multifocal Placoid Pigment Epitheliopathy (APMPPE) Managed With Intravitreal Aflibercept
- Influence of Anti-VEGF Injections on Longitudinal Changes in Vascular Metrics Measured by OCTA in Age Related Macular Degeneration: A Retrospective Real-World Study